Cargando…
A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis
β-arrestins (βarrs) critically mediate desensitization, endocytosis and signaling of G Protein-Coupled Receptors (GPCRs), and they scaffold a large number of interaction partners. However, allosteric modulation of their scaffolding abilities and direct targeting of their interaction interfaces to se...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722207/ https://www.ncbi.nlm.nih.gov/pubmed/28967893 http://dx.doi.org/10.1038/nnano.2017.188 |
_version_ | 1783284971937464320 |
---|---|
author | Ghosh, Eshan Srivastava, Ashish Baidya, Mithu Kumari, Punita Dwivedi, Hemlata Nidhi, Kumari Ranjan, Ravi Dogra, Shalini Koide, Akiko Yadav, Prem N. Sidhu, Sachdev S. Koide, Shohei Shukla, Arun K. |
author_facet | Ghosh, Eshan Srivastava, Ashish Baidya, Mithu Kumari, Punita Dwivedi, Hemlata Nidhi, Kumari Ranjan, Ravi Dogra, Shalini Koide, Akiko Yadav, Prem N. Sidhu, Sachdev S. Koide, Shohei Shukla, Arun K. |
author_sort | Ghosh, Eshan |
collection | PubMed |
description | β-arrestins (βarrs) critically mediate desensitization, endocytosis and signaling of G Protein-Coupled Receptors (GPCRs), and they scaffold a large number of interaction partners. However, allosteric modulation of their scaffolding abilities and direct targeting of their interaction interfaces to selectively modulate GPCR functions have not been fully explored yet. Here, we have identified a series of synthetic antibody fragments (Fabs) against different conformations of βarrs from phage display libraries. Several of these Fabs allosterically and selectively modulated the interaction of βarrs with clathrin and ERK MAP kinase. Interestingly, one of these Fabs selectively disrupted βarr-clathrin interaction, and when expressed as an intrabody, it robustly inhibited agonist-induced endocytosis of a broad set of GPCRs without affecting ERK MAP kinase activation. Our data therefore demonstrate the feasibility of selectively targeting βarr interactions using intrabodies and provide a novel framework for fine-tuning GPCR functions with potential therapeutic implications. |
format | Online Article Text |
id | pubmed-5722207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-57222072018-04-02 A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis Ghosh, Eshan Srivastava, Ashish Baidya, Mithu Kumari, Punita Dwivedi, Hemlata Nidhi, Kumari Ranjan, Ravi Dogra, Shalini Koide, Akiko Yadav, Prem N. Sidhu, Sachdev S. Koide, Shohei Shukla, Arun K. Nat Nanotechnol Article β-arrestins (βarrs) critically mediate desensitization, endocytosis and signaling of G Protein-Coupled Receptors (GPCRs), and they scaffold a large number of interaction partners. However, allosteric modulation of their scaffolding abilities and direct targeting of their interaction interfaces to selectively modulate GPCR functions have not been fully explored yet. Here, we have identified a series of synthetic antibody fragments (Fabs) against different conformations of βarrs from phage display libraries. Several of these Fabs allosterically and selectively modulated the interaction of βarrs with clathrin and ERK MAP kinase. Interestingly, one of these Fabs selectively disrupted βarr-clathrin interaction, and when expressed as an intrabody, it robustly inhibited agonist-induced endocytosis of a broad set of GPCRs without affecting ERK MAP kinase activation. Our data therefore demonstrate the feasibility of selectively targeting βarr interactions using intrabodies and provide a novel framework for fine-tuning GPCR functions with potential therapeutic implications. 2017-10-02 2017-12 /pmc/articles/PMC5722207/ /pubmed/28967893 http://dx.doi.org/10.1038/nnano.2017.188 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Ghosh, Eshan Srivastava, Ashish Baidya, Mithu Kumari, Punita Dwivedi, Hemlata Nidhi, Kumari Ranjan, Ravi Dogra, Shalini Koide, Akiko Yadav, Prem N. Sidhu, Sachdev S. Koide, Shohei Shukla, Arun K. A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis |
title | A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis |
title_full | A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis |
title_fullStr | A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis |
title_full_unstemmed | A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis |
title_short | A synthetic intrabody based selective and generic inhibitor of GPCR endocytosis |
title_sort | synthetic intrabody based selective and generic inhibitor of gpcr endocytosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722207/ https://www.ncbi.nlm.nih.gov/pubmed/28967893 http://dx.doi.org/10.1038/nnano.2017.188 |
work_keys_str_mv | AT ghosheshan asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT srivastavaashish asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT baidyamithu asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT kumaripunita asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT dwivedihemlata asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT nidhikumari asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT ranjanravi asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT dograshalini asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT koideakiko asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT yadavpremn asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT sidhusachdevs asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT koideshohei asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT shuklaarunk asyntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT ghosheshan syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT srivastavaashish syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT baidyamithu syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT kumaripunita syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT dwivedihemlata syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT nidhikumari syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT ranjanravi syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT dograshalini syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT koideakiko syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT yadavpremn syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT sidhusachdevs syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT koideshohei syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis AT shuklaarunk syntheticintrabodybasedselectiveandgenericinhibitorofgpcrendocytosis |